Piramal Pharma Ltd reported its financial results for Q4 and FY2025, achieving 12% year-on-year revenue growth and crossing $1 billion in revenues. The consolidated PAT after exceptional items was Rs 154 crore, reflecting a significant 52% increase compared to the previous period.